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Background: We assessed the effects of providing a package of interventions including small-quantity lipid-based
nutrient supplements (SQ-LNS) containing 0, 5 or 10 mg zinc and illness treatment to Burkinabe children from 9 to
18 months of age, on biomarkers of zinc, iron and vitamin A status at 18 months and compared with a non-intervention
cohort (NIC).
Methods: Using a two-stage cluster randomized trial design, communities were randomly assigned to the intervention
cohort (IC) or NIC, and extended family compounds within the IC were randomly assigned to different treatment groups.
IC children (n = 2435) were provided with 20 g SQ-LNS/d containing 0, 5 or 10 mg zinc, 6 mg of iron and 400 μg of
vitamin A along with malaria and diarrhea treatment. NIC children (n = 785) did not receive the intervention package.
At 9 and 18 months, hemoglobin (Hb), zinc, iron and vitamin A status were assessed in a sub-group (n = 404).
Plasma concentrations of zinc (pZC), ferritin (pF), soluble transferrin receptor (sTfR) and retinol-binding protein
(RBP) were adjusted for inflammation.
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Results: At baseline, 35% of children had low adjusted pZC (<65 μg/dL), 93% were anemic (Hb <110 g/L), 25% had
low adjusted pF (<12 μg/L), 90% had high adjusted sTfR (>8.3 mg/L) and 47% had low adjusted RBP (<0.94 μmol/L),
with no group-wise differences. Compared with the NIC, at 18 months IC children had significantly lower anemia
prevalence (74 vs. 92%, p = 0.001) and lower iron deficiency prevalence (13% vs. 32% low adjusted pF and 41% vs. 71%
high adjusted sTfR, p < 0.001), but no difference in pZC. Mean adjusted RBP was greater at 18 months in IC vs. NIC
(0.94 μmol/L vs. 0.86 μmol/L, p = 0.015), but the prevalence of low RBP remained high in both cohorts. Within the IC,
different amounts of zinc had no effect on the prevalence of low pZC or indicators of vitamin A deficiency, whereas
children who received SQ-LNS with 10 mg zinc had a significantly lower mean pF at 18 months compared to children
who received SQ-LNS with 5 mg zinc (p = 0.034).
Conclusions: SQ-LNS regardless of zinc amount and source provided along with illness treatment improved indicators
of iron and vitamin A status, but not pZC.
Trial registration: NCT00944281 (July 21, 2009).
Keywords: Zinc, SQ-LNS, Lipid-based nutrient supplements, Hemoglobin, Anemia, Plasma zinc concentration, Iron,
Vitamin A, Retinol-binding proteinBackground
Zinc, iron and vitamin A are essential for optimal physical
growth, cognitive development and immune function of
young children [1–5]. Deficiencies of these micronutrients
are prevalent in sub-Saharan Africa, where approximately
one fourth of the population are at risk of zinc deficiency
[6], ~20% of pre-school children suffer from iron defi-
ciency anemia [7], and >40% of children have subclinical
vitamin A deficiency, based on serum retinol concentra-
tion <0.70 μmol/L [8]. These micronutrient deficiencies
often co-exist in low-income populations, and combined
supplementation with zinc, iron and vitamin A is gaining
traction as a strategy to decrease childhood morbidity and
mortality [3, 5, 9, 10].
There are multiple potential interactions among micro-
nutrients when they are co-supplemented. For example,
some studies found that adding zinc to iron supplements
reduced their impact on iron status, although a meta-
analysis of available studies concluded that there was no
significant effect of concomitant zinc supplementation on
the response of iron status indicators and hemoglobin
(Hb) to iron supplementation [10, 11]. Zinc may also
affect vitamin A metabolism through its involvement in
protein synthesis and cellular enzyme functions [12],
but there are only a limited number of studies that have
evaluated the effect of combined zinc and vitamin A
supplementation on vitamin A status, and the results
are inconclusive [12–14].
Home fortification of children’s foods using small-
quantity lipid-based nutrient supplements (SQ-LNS)
providing ~110–120 kcal/day (20 g dose) or medium-
quantity lipid-based nutrient supplements (MQ-LNS)
providing ~250–500 kcal/day (45–90 g dose) is a promis-
ing strategy to support normal linear growth and develop-
ment in young children [15]. Despite reports of beneficialeffects of SQ- and MQ-LNS on children’s growth [16–18],
there is little research on their effects on micronutrient
status, and the available studies have assessed only a few
micronutrients. Plasma zinc concentration (pZC) did
not differ between Malawian children who received 4.5–
7.0 mg zinc via either MQ-LNS (40–60 g) or isocaloric
fortified porridge from 6 to 18 months of age [18]. Daily
supplementation of 6–12 months old Ghanaian children
with SQ-LNS reduced iron deficiency anemia by 32%,
but did not affect zinc status [19]. A recent study from
Honduras found that supplementing children with
MQ-LNS (46 to 70 g; containing 9 mg zinc, 9 mg iron,
400 μg vitamin A and 0.9 μg vitamin B12 per 46 g) from
age 6 to 18 months had no effect on Hb, iron or zinc sta-
tus, but significantly reduced vitamin A and vitamin B12
deficiencies [20].
The objectives of the present study were to assess 1)
the effects of supplementing Burkinabe children from 9
to 18 months of age with different amounts of zinc (0, 5
or 10 mg zinc) in SQ-LNS containing 6 mg iron and
400 μg vitamin A along with the treatment of diarrhea
and malaria on biomarkers of zinc, iron and vitamin A sta-
tus at 18 months; and 2) the combined effect of SQ-LNS
and diarrhea and malaria treatments on these indicators
compared with a non-intervention cohort (NIC).
Methods
Study design
This study was a cluster randomized, partially double-
masked, placebo-controlled trial (the International Lipid-
based Nutrient Supplement-Zinc Trial, iLiNS-ZINC), which
took place in the Dandé Health District in southwestern
Burkina Faso from April 2010 to July 2012. Ethical approval
was provided by the Institutional Review Boards of the
Centre Muraz in Bobo-Dioulasso (Burkina Faso) and the
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separate written, informed consents for participation in the
study and for collection of biological specimens from the
child. The study was registered as a clinical trial with the
U.S. National Institute of Health (https://www.clinicaltrials.-
gov/ct2/results?term=NCT00944281).
This trial included two levels of randomization: 1) the
community and 2) the concession (extended family com-
pound). Thirty-four communities accessible during the
rainy season were stratified by health clinic catchment
area and randomly allocated to intervention cohort (IC,
25 communities) or non-intervention cohort (NIC, 9
communities), in such a way to ensure balanced cohorts
with respect to population size, distance from a paved
road, and distance from the city of Bobo-Dioulasso. A
total of 3220 children 9–10 month of age (~95% of those
screened) were enrolled in the study after meeting all
the enrollment criteria (Fig. 1). Of these, 2435 children
were included in the IC and 785 in the NIC. Children
were considered eligible if they were 8.8 to 9.9 months
of age, were permanent residents of the study area, and
their caregivers planned to be available during the study
period and accepted weekly home visits. Children were
not enrolled in the study when their Hb was <50 g/L,
weight-for-length was <70th percentile of the National
Center for Health Statistics/World Health Organization
(NCHS/WHO) growth reference [21], or they had any
illness warranting hospital referral or potentially interfer-
ing with growth, as reported previously in greater detail
[22, 23] (Fig. 1).
Randomization and blinding
Within the intervention cohort, individual concessions
were randomly assigned to one of eight color codes usingFig. 1 Flow diagram of the biochemistry indicators for iLiNS-Zinc. 1In all grou
day. 2In all groups, no sample at 18 mo either because child failed to providea block randomization list prepared by a statistician from
the University of California Davis. Two colors represented
each treatment group, and all participants, field staff, study
statistician and investigators were blinded to the interven-
tion groups during the trial. Cluster randomization at the
level of the concession was chosen to reduce the risk of
cross-contamination within the family compound through
food sharing.Intervention
Children in the IC were assigned to receive one of the
following daily supplements from 9 to 18 months of age:
1) SQ-LNS without added zinc, and placebo tablet
(LNS-Zn0); 2) SQ-LNS with 5 mg added zinc, and pla-
cebo tablet (LNS-Zn5); 3) SQ-LNS with 10 mg added
zinc, and placebo tablet (LNS-Zn10); or 4) SQ-LNS
without added zinc, and 5 mg zinc tablet (LNS-TabZn5).
Supplementation of children in IC started the day after
the baseline screening. Children in the NIC (N = 785) did
not receive SQ-LNS or tablets from 9 to 18 months of
age, but received SQ-LNS with 10 mg zinc for 9 months
beginning at 18 mo of age after the final blood sample
was collected. Caregivers in the IC communities were
instructed to administer 20 g SQ-LNS per day in two
separate servings, preferably mixed in a small portion
of the child’s meal, and to give the dispersible tablet
once daily at least 30 min away from meals. At enrollment
and throughout the study, the caregivers were advised to
continue breastfeeding and feed diverse foods to the child,
and IC caregivers were reminded that SQ-LNS should not
replace other components of the diet. Adherence was
assessed by obtaining reported information on SQ-LNS
and tablet consumption, collecting any remaining SQ-ps, invited if free of confirmed fever or diarrhea during the enrollment
biological samples or because of dropout
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servation in a subgroup of children, as reported in
more detail elsewhere [24].
At baseline, all children were treated for anemia, fever,
malaria, and caregiver reported diarrhea following the
national health policy in Burkina Faso. Children with
Hb <80 g/L received iron supplements (ferrous sulfate,
2–6 mg iron/kg body weight/d for 30 days, depending
on the anemia severity) and 200 mg mebendazole/d for
three days to treat possible helminthic infections. Chil-
dren with a positive rapid diagnostic test (RDT) for
malaria received malaria treatment for three days (amo-
diaquine-artesunate, 1 tablet/d) and an antipyretic (para-
cetamol, 1/2 tablet/d for three days), and children with
confirmed fever and a negative RDT and no other clinical
symptoms received paracetamol only for three days. Oral
rehydration salts (ORS: 1 sachet/d for 4 days) were given
to children with reported diarrhea. Caregivers in the IC
were advised to start the supplementation even during
illness.Biochemistry subgroup
A subset of 1065 children from the IC and NIC were
randomly selected for the biochemistry subgroup and
asked to provide a venous blood sample as described
below. The biochemistry subgroup included only one child
from a concession to avoid reduced accuracy of estimation
due to intra-cluster correlation, and excluded children
with reported fever or diarrhea symptoms on the day of
enrollment or on the scheduled blood collection day. Chil-
dren were enrolled in the biochemistry subgroup until the
target sample size was reached. This paper reports on data
obtained from children who successfully provided blood
specimens at both 9 and 18 months for analyses of micro-
nutrient status.Sample size for the biochemistry subgroup
The sample size estimate for the micronutrient status as-
sessments was based on the number of children needed
in each group to detect differences in effect size of 0.6
SDs with a significance of p ≤ 0.05 and power ≥0.80 for
group-wise comparisons of pZC among the means of
five groups (the four intervention groups and the NIC),
consistent with the magnitude of effect reported in pre-
vious zinc supplementation trials [10, 25]. The estimated
sample size for the NIC was inflated for an assumed de-
sign effect of 1.5 due to the cluster sampling design,
resulting in an estimated total sample requirement of
374 children in the 5 groups (68 in each of the 4 inter-
vention groups and 102 in the NIC). This target sample
size was increased to a total of 468 children in the 5
groups to allow for 20% attrition.Anthropometry
When the children were 9 months of age, their length
was measured to the nearest 0.1 cm (Seca Model 417,
Hamburg, Germany), and their weight was assessed with
50 g precision (Seca Model 383). The mothers’ height
(Seca Model 217) and weight (Seca Model 874) were
assessed during the same visit. Measurements were car-
ried out in duplicate by one of four trained and stan-
dardized anthropometrists and their assistants. A third
measurement was carried out in case of a disagreement
between the two first measurements of >0.5 cm for
length/height and >0.1 kg for weight. The average of the
two closest values was used in the statistical analysis.
Household demographics and child feeding and
morbidity data
Data on maternal education and marital status were
collected at enrollment. At 9 and 18 months, 24-h and
7-day recall data on food intake frequencies and breast-
feeding patterns were collected for all children. After
enrollment, children in the IC were visited weekly by
trained field agents who delivered the supplements and
collected data on adherence to supplementation [24],
general health status and morbidity symptoms [23].
Treatment was provided in case of reported diarrhea,
reported or confirmed fever, and confirmed malaria, as
described above. Data on high-dose vitamin A supplemen-
tation was collected by the field agents on a monthly basis.
The field agent showed a picture of a high-dose vitamin A
capsule during the interview to help the mother recognize
it and distinguish it from the oral polio vaccine.
Capillary blood hemoglobin and zinc protoporphyrin
concentrations
At the time of enrollment screening, Hb was measured
in a capillary blood specimen, using a Hemocue device
(model Hb 201+, Ängelholm, Sweden), and 300 μL ca-
pillary blood was collected in microcuvettes contain-
ing lithium heparin (CB 300 LH, Sarstedt AG & Co,
Nümbrecht, Germany) and stored in a cold-box for
subsequent analysis of zinc protoporphyrin (ZPP) [26],
as described below.
Venous blood collection and processing
Trained phlebotomists also obtained 5 mL blood from
an antecubital or metacarpal vein from children in the
biochemistry subgroup. The venous specimen was col-
lected into trace element-free lithium heparin vacutainer
tubes (Sarstedt AG & Co, Nümbrecht, Germany) 1–2 h
after the last breastfeeding episode, using the specimen
collection and processing methods recommended by the
International Zinc Nutrition Consultative Group [4]. Blood
samples were stored in a cold-box and transported to the
field laboratory for processing and/or analysis. At the field
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trifuging at 2800 rpm for 10 min. For analysis of pZC, iron
status indicators, retinol-binding protein (RBP) and acute
phase proteins [C-reactive protein (CRP) and α-1-acid
glycoprotein (AGP)], plasma was stored at −20 °C until
shipment to the collaborating laboratories for analysis.Laboratory analyses
PZC was measured using an inductively coupled plasma
optical emission spectrophotometer (Vista; Varian Inc,
Walnut Creek, CA) at the Children’s Hospital of Oakland
Research Institute [27, 28]. Inter- and intra-run coefficients
of variation (CV) of control serum were 2.3% and 1.7%, re-
spectively. Indicators of iron status [plasma ferritin (pF),
soluble transferrin receptor (sTfR)] and vitamin A status
[RBP], and acute phase proteins [CRP and AGP] were ana-
lyzed by ELISA (DBS-Tech in Willstaett, Germany) [29].
The CVs of the different indicators for a pooled plasma
sample were 3.3%, 2.0%, 3.3%, 4.4% and 5.5% for pF, sTfR,
RBP, CRP and AGP, respectively. Retinol (ROH) concentra-
tion was measured in a subset of randomly selected sam-
ples by using high performance liquid chromatography
(HPLC, Agilent 1100) at the University of California, Davis,
using a slight modification of the method described by Bieri
et al. [30]. The CV of a control sample run in triplicate with
each batch of plasma ROH samples was 2.6% within the
same run and 2.7% between runs. ZPP was assessed in ca-
pillary blood samples at the field laboratory using a hemato-
fluorometer (206D, AVIV Biomedical Inc., Lakewood, NJ,
USA) after a maximum of 4 days of storage in the refriger-
ator, during which ZPP is considered stable [31]. Samples
were analyzed in duplicate, unless inadequate volume only
allowed for one measurement.Validation of the RBP cutoff for vitamin A deficiency
Cutoffs for determining vitamin A deficiency based on
RBP differ among populations [32], so we determined a
cutoff for our study population by measuring both ROH
and RBP concentrations in a subset of 40 randomly se-
lected samples. Logarithm-transformed ROH values were
tested for their correlation with logarithm-transformed
RBP values from the same child at the same age using the
Pearson correlation test, and a linear regression was gener-
ated (Proc GLM). There was a high correlation between
ROH and RBP measured in the 40 samples (R = 0.78,
p < 0.0001). To derive the corresponding RBP cutoff
for vitamin A deficiency, a regression model used was:
Log ROH = −0.30 + 0.87 (log RBP). In this population,
the RBP cutoff corresponding to 0.70 μmol ROH/L is
0.94 μmol RBP/L. The sensitivity of this population-
adjusted cutoff to detect low ROH (<0.70 μmol/L) was
82% and the specificity was 83%.Data analysis
All statistical analyses were carried out using SAS software
for Windows (9.3, SAS Institute, Cary, North Carolina).
Descriptive statistics (means, geometric means (95%
confidence interval) and proportions) were used to as-
sess baseline information by group, and to compare
children included in the biochemistry subgroup with
those not included. Variables that were not normally
distributed were transformed using Box-Cox transfor-
mations to find the optimal transformation. Analysis
was done with logarithm-transformed variables, which
were back transformed for reporting of descriptive results.
Plasma concentrations of zinc, pF, sTfR and RBP and
capillary whole blood ZPP were adjusted categorically
for the presence of inflammation [33]. Participants were
stratified into four inflammation categories based on ele-
vation of one or both acute phase proteins, or no inflam-
mation using the method described by Thurnham et al.
[33], and cutoffs of 5 mg/L for CRP and 1 g/L for AGP.
Body iron stores (BIS) were calculated using the ratio of
both adjusted and unadjusted sTfR and pF concentra-
tions using the formula developed by Cook et al. [34].
Micronutrient deficiencies were defined using the fol-
lowing cutoffs, for both adjusted and unadjusted values:
zinc deficiency (pZC <65 μg/dL) [4], anemia (Hb <110 g/L)
[35], iron deficiency [ID, pF <12 μg/L [36], sTfR >8.3 mg/L,
BIS <0 mg/kg, and ZPP >70 μmol/mol heme [37]], and vita-
min A deficiency (RBP <0.94 μmol/L). Additionally, iron
deficiency anemia (IDA) was defined as having both anemia
and ID, as outlined above.
Length-for-age z-score (LAZ) and weight-for-length z-
score (WLZ) were calculated in relation to the World
Health Organization Child Growth Standards using SAS
macros [38]. Breastfeeding and 24 h-complementary
feeding indicators were constructed according to World
Health Organization guidelines [39]. 7-day intake of
vitamin-A rich fruits and vegetables were summarized as
continuous scores ranging from 0 to 7. Consumption
frequencies of vitamin A-rich fruits and vegetables were
also categorized dichotomously (<3 or ≥3 d/week). Defi-
nitions of infectious diseases identified in IC children
are reported in more detail elsewhere [22, 23]. Briefly,
diarrhea was defined as caregiver report of three or more
liquid or semi-liquid stools during a 24-h period. An epi-
sode of diarrhea was defined as the period starting the
day the child first had diarrhea preceded and followed
by a two-day, diarrhea-free period. Fever was defined as
any fever reported by the caregiver or elevated auricular
temperature (>37.5 °C), as measured by the field
workers. An episode of fever was defined as the period
starting the day the child first had fever preceded and
followed by two days when the child had not had fever.
Malaria was defined as the presence of reported or con-
firmed fever during the 24 h preceding the morbidity
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malaria was defined as the presence of a new episode of
reported or confirmed fever and a positive malaria
RDT obtained >21 days after a previous treated malaria
episode.
Outcomes for inflammation, zinc, iron and vitamin A
status and changes in the outcomes between baseline
and at 18 months were compared by intervention group
and cohort using analysis of covariance for continuous
outcome variables and logistic regression for dichotom-
ous variables. Differences in the outcomes between base-
line and at 18 months were tested using repeated
measurement of covariance for continuous outcomes
and the random statement of the logistic regression for
dichotomous variables. Analysis included a random ef-
fect of the community to account for intra-community
correlation. Intervention group and cohort were used as
the main effects, and covariates were tested individually
in a binary model with the outcome before including the
variables with p < 0.1 in the final model. All the outcomes
were adjusted for baseline values. Covariates tested were
previously listed in our plan of analysis, which was written
before the study code was broken, and included child age,
sex, baseline anthropometric characteristics and maternal
and household characteristics, study season and 18
months acute phase proteins. Indicators of iron status and
RBP were adjusted additionally for baseline RDT, iron sup-
plementation and breastfeeding and 24-h complementary
feeding indicators. Covariates which were significantly as-
sociated with the outcome were tested for their potential
modifying effect of the intervention groups and cohort.
We also tested baseline pZC for its potential modifying ef-
fect of the intervention cohort and group, and recent
high-dose vitamin A supplementation of the intervention
groups on RBP at 18 months within the IC. Intervention
group means were compared post-hoc using least-square
means with the Tukey-Kramer test. Tables report the
comparison among the four intervention groups and
between the combined intervention groups and the
non-intervention cohort (IC vs. NIC). Additional 5-group
comparisons were conducted and reported only when
deemed helpful to clarify subtle differences in the results.
Results
Baseline characteristics
Among the 1065 children randomly selected for possible
participation in the biochemistry sub-group, 66% (n = 701)
were eligible on the scheduled day (i.e. free of symptom-
atic diarrhea and fever, as reported by the caregiver).
Among the eligible children, a venous blood sample was
successfully collected in 60% (n = 414) at 9 months.
Among those, 404 children successfully provided blood
samples at both 9 and at 18 months and are included in
this analysis (Fig. 1).Children who provided venous blood samples did not
differ from those who did not, except that a higher pro-
portion of the children who provided samples had a
positive initial RDT (67 vs. 61% respectively, p = 0.015).
At baseline, 23% of children in the biochemistry sub-
group were stunted, 32% were underweight and 18%
were wasted. Anemia prevalence was high, affecting 93%
of children in the biochemistry subgroup. At enrollment,
one-third of the children had Hb concentration <80 g/L
and received iron supplementation and antihelminthic
treatment, and two-thirds were treated for positive malaria
RDT. All children were still breastfed, and almost all chil-
dren had started eating some type of complementary food.
In particular, 83% of children reportedly received cereal-
based foods and only 7 and 13%, respectively, consumed
legumes and flesh food on the previous day (Table 1).
Inflammation indicators
At baseline, 4% of children had elevated CRP only, 33%
had both elevated CRP and AGP and 30% had elevated
AGP only, with no significant differences among the
intervention groups or cohorts. Mean AGP and CRP
concentrations at 18 months did not differ significantly
by intervention cohort or by intervention group within
the IC. Compared to the NIC, the IC had a lower preva-
lence of children who had elevated CRP only and both ele-
vated CRP and AGP, and a greater proportion of children
who had elevated AGP only at 18 months (2, 27 and 31%,
respectively for IC children compared to 5%, 37% and 23%
for NIC children, p = 0.03), but the total percentage of
children with inflammation remained high for both co-
horts at 18 months.
Plasma zinc concentration
At baseline, 35% of the children had low pZC after adjust-
ment for inflammation. The proportion of children with
low pZC increased from 9 to 18 months (p < 0.0001), but
did not differ among the intervention groups or between
the cohorts at 18 months (Table 2). From 9 to 18 months,
mean pZC decreased significantly from 67.1 to 63.6 μg/dL
in the NIC and from 69.5 to 64.8 μg/dL in the IC (p <
0.0001). The change in pZC was not significantly different
between the two cohorts (p = 0.39), nor by intervention
group (p = 0.84). AGP and CRP were significantly associ-
ated with pZC at 18 months, but did not modify the effect
of intervention group or cohort on final pZC.
Hemoglobin concentration
At baseline, the mean Hb concentration for all groups
combined was 88 g/L, and 93% of the children were
anemic. At 18 months, the prevalence of anemia decreased
by one-fifth in the IC, but did not change in the NIC
(Tables 3 and 4). Nevertheless, 74% of the children in
Table 1 Child, maternal and household characteristics of study participants assessed for biochemical status, by study group
LNS-Zn0 LNS-Zn5 LNS-Zn10 LNS-TabZn NIC p-value for the difference
among 5 groupsa,b
N (children with 9 and 18 mo values) 84 75 79 73 93
N boys (%) 38 (45.2) 41 (54.7) 31 (39.2) 38 (52.0) 40 (49.5) 1.000
Baseline child LAZ −1.29 ± 1.00 −1.25 ± 1.04 −1.14 ± 1.08 −1.11 ± 1.10 −1.14 ± 1.08 0.783
Baseline child WLZ −1.03 ± 1.20 −0.92 ± 1.04 −1.13 ± 0.91 −0.86 ± 1.05 −1.05 ± 1.11 0.506
N Baseline iron supplementation (%)c 20 (23.8) 21 (28.0) 21 (26.6) 23 (31.5) 29 (31.2) 0.828
N Baseline RDT positive (%) 62 (73.8) 49 (65.3) 54 (68.3) 47 (64.4) 58 (62.4) 0.479
Maternal body mass index (kg/m2) 20.5 ± 1.7 20.8 ± 2.3 21.1 ± 2.6 21.0 ± 2.3 20.4 ± 2.3 0.164
Maternal education 0.383
No formal or informal education 53 (63.1) 47 (62.7) 51 (64.6) 43 (58.9) 68 (73.1)
Any informal education and/or less than
one year of formal education
24 (28.6) 21 (28.0) 19 (24.0) 18 (24.7) 17 (18.3)
At least one year of formal education 7 (8.3) 7 (9.3) 9 (11.14) 12 (16.4) 8 (8.6)
Baseline child feeding practices
Child still breastfed (%) 84 (100) 75 (100) 79 (100) 73 (100) 93 (100) 1.000
Animal source foodd 21 (25.0) 18 (24.0) 15 (19.0) 22 (30.1) 22 (23.7) 0.621
Child morbidity during the interventione
Child malaria incidence (episodes per
100 child days at risk)
0.60 ± 0.48 0.62 ± 0.53 0.58 ± 0.48 0.64 ± 0.54 – 0.339
Child fever incidence (episodes/100
child-days at risk)
1.28 ± 0.84 1.34 ± 0.94 1.51 ± .1.19 1.39 ± 0.95 – 0.683
Child diarrhea incidence (episodes per
100 child days at risk)
1.02 ± 0.90 0.82 ± 0.66 0.92 ± 0.80 0.92 ± 0.92 – 0.469
LAZ length for age z-score, WLZ weight for length z-score
aValues presented are means ± SD, n (%)
bP-values are from mixed model for continuous variables, logistic regression for binary variables and Chi square for polychotomous variables. All analyses were
adjusted for the random effect of village, and in morbidity outcomes, were controlled for over-dispersion
cChildren with Hb <80 g/L received ferrous sulfate, 2–6 mg iron/kg body weight/d for 30 days, depending on the anemia severity and 200 mg mebendazole/d for
three days to treat possible helminthic infections
dChild consumed at least one animal-source food during the previous 24 h
eMorbidity outcomes include children in the IC who provided data on ≥30 days
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differences among the four intervention groups.
The presence of inflammation and study season were
significantly associated with final Hb concentration, but
only the study season modified the effect of intervention
group and cohort on final Hb. In particular, Hb concen-
tration increased significantly in IC children who spent
≥5 months in the study during the rainy season (96 g/L
in the IC vs. 82 g/L in NIC, p = 0.0003), while the Hb re-
sponse did not differ significantly in children who partic-
ipated in the study mostly during the dry season (99 g/L
in IC vs. 95 g/L in NIC, p = 0.86).
Iron status
Iron status indicators were affected by the presence of
inflammation (Tables 3 and 4), so the results are pre-
sented after adjusting for these effects. The estimated
prevalence of iron deficiency differed by iron status indi-
cator. In particular, at 9 months, 25% of the children hadlow adjusted pF, 90% had high adjusted sTfR, 56% had
low adjusted BIS and 96% had high adjusted ZPP. 24%
of children had IDA as defined by the simultaneous
presence of anemia and low adjusted pF, and 85% had
IDA as defined by anemia and elevated adjusted sTfR.
There was no effect of supplementing different amounts
and sources of zinc on any of the iron status indicators ex-
cept for pF and BIS. Children who received LNS-Zn10
had a lower adjusted geometric mean pF and BIS com-
pared to LNS-Zn5 (22.1 μg/L vs. 30.5 μg/L, p = 0.034 for
pF; and 2.21 mg/kg vs. 3.35 mg/kg, p = 0.047 for BIS), al-
though the prevalence of low adjusted pF and low adjusted
BIS was not significantly different among intervention
groups. In a 5-group analysis, adjusted geometric mean pF
of children who received LNS-Zn10 was not significantly
different from children in the NIC (p = 0.298).
The prevalence of ID at 18 months, as defined by ad-
justed pF, was significantly different between the two
cohorts (p < 0.0001). In particular, the prevalence of ID
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Table 4 Effect of SQ-LNS containing different amounts and sources of zinc along with malaria and diarrhea treatment on prevalence
of anemia, iron deficiency and iron deficiency anemia in children aged 9 – 18 months
LNS-Zn0 LNS-Zn5 LNS-Zn10 LNS-TabZn5 P-value among 4
intervention groupsb
IC NIC P-value between
cohortsb
% Anemia (Hb <110 g/L)a
At 9 months, N (%) 76 (95.0) 69 (94.5) 72 (94.7) 62 (91.2) 0.794 279 (93.9) 80 (91.9) 0.515
At 18 months, N (%) 62 (77.5) 57 (78.1) 52 (68.4) 48 (70.6) 0.503 219 (73.7) 80 (91.9) 0.0007
% Low plasma ferritin (pF <12 μg/L)
Low unadjusted pF at
9 months, N (%)
12 (14.3) 10 (13.3) 9 (11.4) 10 (13.7) 0.950 41 (13.2) 11 (11.8) 0.575
Low adjusted pF at
9 months, N (%)
18 (21.4) 25 (33.3) 12 (15.2) 17 (23.3) 0.049 72 (23.1) 29 (31.2) 0.126
Low unadjusted pF at
18 months, N (%)
4 (4.8) 2 (2.7) 6 (7.6) 6 (8.2) 0.476 18 (5.8) 19 (20.4) <0.0001
Low adjusted pF at 18
months, N (%)
9 (10.7) 6 (8.0) 16 (20.2) 11 (15.1) 0.109 42 (13.5) 30 (32.3) 0.0001
% Elevated soluble transferrin receptor (sTfR >8.3 mg/L)
High unadjusted sTfR at
9 months, N (%)
77 (91.7) 73 (97.3) 75 (94.9) 70 (95.9) 0.355 295 (94.8) 84 (90.3) 0.100
High adjusted sTfR at
9 months, N (%)
71 (84.5) 71 (94.7) 73 (92.4) 69 (94.5) 0.080 284 (91.3) 79 (84.9) 0.163
High unadjusted sTfR at
18 months, N (%)
38 (45.2) 37 (49.3) 41 (51.9) 36 (49.3) 0.884 152 (48.9) 70 (75.3) 0.001
High adjusted sTfR at
18 months, N (%)
31 (36.9) 30 (40.0) 35 (44.3) 31 (42.5) 0.725 127 (40.8) 66 (71.0) <0.0001
% Low body iron stores (BIS <0 mg/kg)
Low unadjusted BIS at
9 months, N (%)
31 (36.9) 37 (49.3) 33 (41.8) 29 (39.7) 0.260 130 (41.8) 38 (40.9) 0.782
Low adjusted BIS at
9 months, N (%)
37 (44.0)b 50 (66.7)a 44 (55.7)ab 39 (53.4)ab 0.049 170 (54.7) 58 (62.4) 0.248
Low unadjusted BIS at
18 months, N (%)
8 (9.5) 7 (9.3) 11 (13.9) 11 (15.1) 0.641 37 (11.9) 31 (33.3) 0.0001
Low adjusted BIS at
18 months, N (%)
9 (10.7) 15 (20.0) 16 (20.3) 16 (21.9) 0.385 56 (18.0) 43 (46.2) <0.0001
% Elevated capillary zinc protoporphyrin (ZPP >70 μmol/mol heme)
High unadjusted ZPP at
9 months, N (%)
78 (96.3) 71 (97.3) 79 (100.0) 71 (97.3) 1.000 299 (97.7) 84 (91.3) 0.968
High adjusted ZPP at
9 months, N (%)
78 (96.3) 71 (97.3) 79 (100.0) 71 (97.3) 1.000 299 (97.7) 84 (91.3) 0.968
High unadjusted ZPP at
18 months, N (%)
80 (98.8) 71 (97.3) 78 (98.7) 72 (98.6) 0.844 301 (98.4) 92 (100.0) 0.982
High adjusted ZPP at
18 months, N (%)
80 (98.8) 71 (97.3) 78 (98.7) 72 (98.6) 0.844 301 (98.4) 92 (100.0) 0.982
Iron deficiency anemia
% Low plasma ferritin and anemia
Low unadjusted pF and anemia
at 9 months, N (%)
11 (13.8) 10 (13.7) 8 (10.5) 10 (14.7) 0.933 39 (13.1) 10 (11.5) 0.632
Low adjusted pF and anemia
at 9 months, N (%)
15 (18.8) 24 (32.9) 11 (14.5) 17 (25.0) 0.064 67 (22.6) 27 (31.0) 0.130
Low unadjusted pF and anemia
at 18 months, N (%)
3 (3.8) 1 (1.4) 5 (6.6) 4 (5.9) 0.449 13 (4.4) 17 (19.5) <0.0001
Low adjusted pF and anemia
at 18 months, N (%)
8 (10.0) 3 (4.1) 13 (17.1) 8 (11.8) 0.067 32 (10.8) 25 (28.7) 0.0002
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Table 4 Effect of SQ-LNS containing different amounts and sources of zinc along with malaria and diarrhea treatment on prevalence
of anemia, iron deficiency and iron deficiency anemia in children aged 9 – 18 months (Continued)
% Elevated soluble transferrin receptor and anemia
High unadjusted sTfR and
anemia at 9 months, N (%)
71 (88.8) 68 (93.2) 68 (89.5) 60 (88.2) 0.656 267 (89.9) 75 (86.2) 0.667
High adjusted sTfR and anemia
at 9 months, N (%)
67 (83.8) 66 (90.4) 66 (86.8) 59 (86.8) 0.427 258 (86.9) 70 (80.5) 0.490
High unadjusted sTfR and
anemia at 18 months, N (%)
32 (40.0) 29 (39.7) 28 (36.8) 27 (39.7) 0.852 116 (39.1) 63 (72.4) 0.001
High adjusted sTfR and anemia
at 18 months, N (%)
26 (32.5) 24 (32.9) 22 (28.9) 24 (35.3) 0.882 96 (32.3) 59 (67.8) <0.0001
Hb hemoglobin concentration, pF plasma ferritin, sTfR soluble transferrin receptor, ZPP zinc protoporphyrin
an (%)
bValues in a row with superscripts with different letters differ P < 0.05, using Proc GLIMMIX. Values are adjusted for the cluster effect of the village
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−42%), whereas it did not change in the NIC (Fig. 2).
Similarly, the prevalence of ID, when defined by ad-
justed BIS, was significantly different between the two
cohorts at 18 months and only fell significantly in the
IC over the course of the study (Fig. 2). In contrast, the
prevalence of elevated adjusted ZPP did not differ by
cohort and increased from 96% to 99% (p = 0.01). The
difference in prevalence of ID between IC and NIC was
similar whether or not the indicators were adjusted for
inflammation (Table 4). IDA was lower in both cohorts
at 18 months, but decreased significantly only in the IC
(IDA defined by pF decreased relatively by 51% in the
IC vs. 7% in NIC, and IDA defined by sTfR decreased
relatively by 63% in the IC vs. 16% in the NIC).
Vitamin A status
At baseline, adjusted RBP concentration did not differ
by intervention group or cohort, with a geometric mean*
*
-80
-70
-60
-50
-40
-30
-20
-10
0
10
20
Low pF High sTfR L
)
%(
ec
nelaver
p
ni
e
g
na
h
C
Intervention cohort
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ship between reported consumption of vitamin A rich
fruits and RBP concentration. Twelve percent of children
in the IC reportedly received a high-dose vitamin A sup-
plement during the month preceding the biochemistry
visit at 18 months. However, reported receipt of high-
dose vitamin A supplement was not associated with RBP
concentration at 18 months. Similarly, RBP concentration
at 18 months was not significantly related to baseline
pZC, and pZC did not modify the effect of intervention
group or cohort on final RBP concentration.
Discussion
Different amounts of zinc provided either in SQ-LNS or
as a dispersible zinc tablet did not affect the final pZC
or other markers of micronutrient status, except for the
lower final mean pF concentration and lower BIS in chil-
dren who received LNS-Zn10 compared to those who
received LNS-Zn5. By contrast, SQ-LNS, provided along
with malaria and diarrhea treatment in the intervention
cohort, increased the children’s final iron status, Hb con-
centration and vitamin A status, compared with those in
the non-intervention cohort. The intervention package
also reduced the prevalence of iron deficiency, anemia
and IDA, compared with the NIC, although most chil-
dren remained anemic at 18 months. Hb concentration
increased significantly more among children in the IC
who participated in the study mostly during the rainy
season, when food is generally less available and malaria
and diarrhea are more common, suggesting that the
benefit may be greatest during periods of food insecurity
and/or more frequent infections.
One third of children had subclinical zinc deficiency at
baseline and more than half of all children had subclin-
ical zinc deficiency at endline. Thus, zinc deficiency is a
public health concern in the study population [40].
Nevertheless, the lack of a change in pZC after zinc sup-
plementation with the dispersible tablet differs from the
results of multiple other studies [10], including a short-
term study completed in the same geographic region in
which supplements were given under direct observation
and produced a sizeable increase in pZC [28]. The lack
of change in pZC among children supplemented with
zinc tablets in the present study could indicate low ad-
herence to supplementation with tablets or failure to
provide the tablets between meals. In fact, we have pre-
viously reported that tablet adherence was less than 30%
in a subgroup of children who were observed for 12 h at
home; and more than half of the time, the tablet was
given less than 30 min after either a meal or SQ-LNS
had been served, contrary to what was recommended ac-
cording to the study protocol [24]. The lack of change in
pZC among children who received additional zinc through
SQ-LNS is consistent with results from most previous trialsthat provided supplemental zinc mixed with food [19, 41–
43]. Zinc provided with food is presumably less well
absorbed than when provided as a tablet or syrup apart
from meals, or the absorbed zinc is metabolized differently
post-absorption.
Zinc supplementation had no effect on Hb concentra-
tion and anemia prevalence, regardless of the dose or form
of supplementation. This is in agreement with a meta-
analysis of zinc supplementation trials, which found that
daily zinc supplementation (10–20 mg) among children
<15 years of age had no effect on Hb concentration [44].
Zinc supplementation also had no effect on most iron sta-
tus indicators except for the lower pF concentration and
lower BIS found in children who received LNS-Zn10, pos-
sibly due to inhibition of iron absorption in the presence
of higher amounts of zinc. Nevertheless, iron status was
increased by concurrent supplementation of zinc and iron
despite the slightly smaller magnitude of response with
the higher dose of zinc [10, 11].
Provision of supplemental zinc did not significantly
affect the final prevalence of vitamin A deficiency or mean
adjusted RBP at 18 months. Previous studies on the im-
pact of adding zinc to vitamin A supplements on vitamin
A status have yielded inconsistent results [12–14]. Smith
suggested that the effect of zinc on response to vitamin A
supplementation may be conditioned by the severity of
zinc deficiency [45]. This was not confirmed in our study.
Although zinc deficiency was a public health concern in
the study population baseline pZC had no effect on the re-
sponse of RBP to zinc supplementation.
Anemia prevalence was reduced by 20% in the IC, but
most children were still anemic at 18 months, and
anemia remained a severe public health problem in this
population. Because SQ-LNS provided the recommended
daily allowance of more than 20 micronutrients [15], in-
cluding iron, vitamin A and vitamin B12, other factors,
such as malaria, intestinal helminthes, other infections
and hemoglobinopathies may have contributed to the high
anemia burden [46]. However, in a separate analysis
including only children from the IC, the frequency of
malaria episodes during the 9 months of the intervention
was not associated with the change in Hb concentration
or anemia prevalence at 18 months [47].
At 18 months, the intervention reduced the prevalence
of ID by 39–45% compared with the NIC, depending on
the ID indicator. Almost all children had high ZPP at 18
months, which suggests that ZPP may not be a useful in-
dicator of iron status in this population due to the high
burden of malaria and other infections. Previous studies
indicate that ZPP values may be falsely increased in indi-
viduals with infections, chronic inflammation, hemoglo-
binopathies and high lead intakes [48–52].
Our findings regarding the effects of SQ-LNS on Hb and
iron status are similar to results from LNS interventions in
Abbeddou et al. BMC Pediatrics  (2017) 17:46 Page 15 of 17other low-income countries. In a study in Ghana, 6 months
old infants supplemented for 6 months with SQ-LNS
containing 9 mg iron/daily dose also had increased iron
status and lower anemia prevalence compared to a
non-intervention group [19]. In a randomized clinical
trial in Malawi, moderately malnourished children 6–
18 months of age who received 25 g/d of a milk-based
fortified spread for 12 weeks had a greater change in
Hb (mean ± SD: 11 ± 21 g/L) compared to children who
did not receive any supplement (1 ± 20 g/L) [53]. In
contrast, supplementation of 6–18 months old children
with MQ-LNS (46 to 70 g, containing 400 μg vitamin
A, 9 mg iron and 9 mg zinc per 46 g) did not affect
iron status, Hb concentration or prevalence of anemia
during an efficacy trial in rural Honduras compared to
a control population who received, similarly to the
intervention population, food vouchers and nutrition
counselling [20]. Our findings are also similar to results
of trials of micronutrient powders (MNP), which pro-
vide 12 mg iron, 300 μg retinol and 5 mg zinc per daily
dose. A recent meta-analysis found that daily MNP
supplementation among 6–23 months old children re-
duced anemia prevalence by 31% and iron deficiency by
51% compared to placebo or no intervention [54, 55].
The intervention package increased mean plasma RBP
concentration, but did not affect the prevalence of low
RBP concentration. Similarly, supplementing 6–18 months
old Honduran children with MQ-LNS containing 400 μg
vitamin A significantly increased plasma retinol concen-
tration after 6 months compared to a control group, al-
though this difference was no longer present after 12
months of supplementation [20].
Our study has several strengths including: 1) the dif-
ferent micronutrient status indicators examined; 2) the
large sample size; 3) the continuous training and super-
vision of field workers responsible for collecting data
and obtaining the biological samples; and 4) the post-
hoc calculated design effect (1.0–1.7) was accounted for
by the inflated sample size in the NIC, which shows that
our effective sample size has not been reduced greatly
for most of the indicators. We also recognize several
limitations of our study, which include the lack of an ill-
ness treatment only cohort to differentiate between the
effect of SQ-LNS supplementation and the effect of
malaria and diarrhea treatment. In addition, due to the
lack of information on malaria infection at 18 months,
we could not adjust pF and RBP for the presence of
asymptomatic malaria, as recently proposed by Wessells
et al. [56].
Conclusions
Our results indicate that supplemental zinc provided in
SQ-LNS or as a dispersible tablet increased Hb and vita-
min A status. Although children who received SQ-LNScontaining 10 mg zinc had a lower pF response than
those who received SQ-LNS containing less zinc, there
were no group-wise differences in the final prevalence of
ID or anemia in the IC. The lack of a change in pZC
after supplementation with a zinc tablet containing 5 mg
zinc and with SQ-LNS containing 5 or 10 mg zinc sug-
gests possible low adherence to the dispersible tablet
and/or poor absorption of supplemental zinc when pro-
vided with food, or different post-absorptive metabolism
of zinc when absorbed. Despite the lack of an effect of
zinc supplementation in this study population, SQ-LNS
along with malaria and diarrhea treatment was beneficial
in reducing the prevalence of ID and anemia and in-
creasing vitamin A status in young children.
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